Growth Hormone News and Research

RSS

Growth hormone (GH) is a protein-based peptide hormone. It stimulates growth, cell reproduction and regeneration in humans and other animals. Growth hormone is a 191-amino acid, single-chain polypeptide that is synthesized, stored, and secreted by the somatotroph cells within the lateral wings of the anterior pituitary gland.

Researchers find persistent gender bias in provision of growth hormone treatment for idiopathic short stature

Short boys are three times more likely than short girls to receive recombinant human growth hormone treatment for idiopathic short stature (ISS), even though in a general pediatric population, equal proportions of both genders fall under the height threshold designating ISS. Researchers who analyzed records of over 283,000 U.S. children and adolescents found a clear-cut and persistent gender bias in the provision of treatment.

11 Jun 2015

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Today, Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall survival (OS) and overall response rate (ORR) in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL, respectively) in the final analysis of the Phase III RESONATE™-2 (PCYC-1115) trial.

5 Jun 2015

Study on human growth hormone for ACL tear recovery receives funding from Mark Cuban Foundation

Funding from the Mark Cuban Foundation, run by the well-known owner of the Dallas Mavericks, will allow University of Michigan scientists and physicians to study how human growth hormone may aid recovery from an ACL tear - one of the most frequent, traumatic and dreaded knee injuries among athletes.

1 Jun 2015

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.

1 Jun 2015

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.

1 Jun 2015

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR.

1 Jun 2015

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Pharmacyclics, Inc. today announced the initiation of PCYC-1136-CA, a multi-center study that will investigate the use of ibrutinib (IMBRUVICA®) in combination with MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor being developed by AstraZeneca.

1 Jun 2015

Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

Biscayne Pharmaceuticals, Inc., today announced that data supporting the anti-cancer potential of its growth hormone-releasing hormone (GHRH) technology will be discussed in a poster presentation at the 2015 ASCO Annual Meeting.

28 May 2015

Individualised GH dosing provides cost-effective catch-up growth in ISS

Treating children with idiopathic short stature with an individualised, formula-based dose of recombinant human growth hormone induces equivalent catch-up growth to that achieved with a standard dose, show findings from a randomised trial.

27 May 2015

No evidence for cancer risk with growth hormone therapy

There is no evidence that growth hormone (GH) therapy increases the likelihood of neoplasms in children with no additional risk factors, says the Pediatric Endocrine Society Drug and Therapeutics Committee.

1 May 2015

Ascendis reports results from Phase 1 single ascending dose study of TransCon Treprostinil

Ascendis Pharma A/S, a clinical stage biotechnology company that applies its TransCon technology to address significant unmet medical needs, announced today that its Phase 1 single ascending dose study of TransCon Treprostinil produced dose-dependent increases in plasma treprostinil levels in-line with expectations.

29 Apr 2015

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) data presented yesterday by Pharmacyclics, Inc. at the American Association for Cancer Research Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma (PDAC), as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft (PDX) mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse).

20 Apr 2015

Aeterna Zentaris plans to conduct Macrilen Phase 3 clinical study for AGHD

Aeterna Zentaris Inc. today announced plans to conduct a new, confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency ("AGHD"), as well as a dedicated thorough QT study to evaluate the effect of Macrilen on myocardial repolarization.

13 Apr 2015

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics, Inc. today announced longer-term data from a Phase II investigator-initiated study showing Waldenstrom's macroglobulinemia (WM) patients treated with IMBRUVICA (ibrutinib) experienced sustained disease control with an overall response rate (ORR) of 91% after a median of 19.1 months of treatment and a 2-year overall survival (OS) rate of 95%.

9 Apr 2015

Combined therapy boosts growth in short children with low IGF-1

Children with short stature benefit from receiving combined treatment with growth hormone and insulin-like growth factor-1, if they have low endogenous levels of the latter, a study shows.

1 Apr 2015

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Novo Nordisk today announced the company will launch Novoeight (Antihemophilic Factor [Recombinant]) in the United States for people living with hemophilia A.

From Novo Nordisk 26 Mar 2015

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Pharmacyclics, Inc. today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA) will be highlighted at the 2015 American Association for Cancer Research Annual Meeting to be held April 18 – 22, 2015, in Philadelphia, PA.

19 Mar 2015

GH response poor in SGA children with good spontaneous catch-up growth

Spontaneous catch-up growth after birth in short children who were born small for gestational age is a negative predictor of their long-term response to growth hormone treatment, say researchers.

13 Mar 2015

Chiasma closes $70 million Series E financing round

Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, today announced the closing of a $70 million Series E financing round.

27 Feb 2015

Study: Growth hormone can improve social impairment in patients with Phelan-McDermid syndrome

A growth hormone can significantly improve the social impairment associated with autism spectrum disorder (ASD) in patients with a related genetic syndrome, according to a pilot study conducted at the Icahn School of Medicine at Mount Sinai and published yesterday on Pub Med, a public database of biomedical topics maintained by the National Institutes of Health (study originally published in the December 12 issue of the journal Molecular Autism).

20 Feb 2015

Growth Hormone News and Research

Further Reading

Researchers find persistent gender bias in provision of growth hormone treatment for idiopathic short stature

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Study on human growth hormone for ACL tear recovery receives funding from Mark Cuban Foundation

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

Individualised GH dosing provides cost-effective catch-up growth in ISS

No evidence for cancer risk with growth hormone therapy

Ascendis reports results from Phase 1 single ascending dose study of TransCon Treprostinil

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Aeterna Zentaris plans to conduct Macrilen Phase 3 clinical study for AGHD

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Combined therapy boosts growth in short children with low IGF-1

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

GH response poor in SGA children with good spontaneous catch-up growth

Chiasma closes $70 million Series E financing round

Study: Growth hormone can improve social impairment in patients with Phelan-McDermid syndrome

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News